Michon J M, Gey A, Moutel S, Tartour E, Meresse V, Fridman W, Teillaud J L
INSERM Unité 255, Institut Curie, Paris, France.
Br J Haematol. 1998 Mar;100(3):550-6. doi: 10.1046/j.1365-2141.1998.00597.x.
Neutrophils from 13 children who received G-CSF for the collection of peripheral blood progenitors while they were in haematological steady state were studied at various times after G-CSF injection for Fc gammaR expression (Fc gammaRI or CD64, Fc gammaRII or CD32, and Fc gammaRIII or CD16) and for their ability to exert antibody-dependent cell cytotoxicity (ADCC) through Fc gammaRI. Changes in IFNgamma, IL8, IL10, MCP1 and TNF alpha mRNA levels in peripheral blood cells were also studied 4 h and 24 h after the first G-CSF injection. Fc gammaRI expression increased strongly after 24 h and then remained at the same level throughout treatment. In contrast, Fc gammaRIII expression sharply decreased at day 1 and diminished even further thereafter. No change in Fc gammaRII was observed. ADCC exerted by neutrophils through Fc gammaRI started to increase after 24 h with the peak level at day 5. Cytokine mRNA analyses indicated a reproducible and strong increase of IL8 mRNA (11/13 children) after 24 h, whereas the changes in the mRNA levels of the other cytokines tested were more heterogenous (TFNgamma: three; IL10: six; MCP1: five: TNF alpha: four, of the 13 children). Therefore this study opens the way to an optimized therapeutic schedule for the combined use of G-CSF and monoclonal antibodies in adjuvant immuno-intervention.
对13名在血液学稳定状态下接受粒细胞集落刺激因子(G-CSF)以采集外周血祖细胞的儿童的中性粒细胞进行了研究,在注射G-CSF后的不同时间点检测其FcγR表达(FcγRI或CD64、FcγRII或CD32以及FcγRIII或CD16),并检测其通过FcγRI发挥抗体依赖性细胞毒性(ADCC)的能力。在首次注射G-CSF后4小时和24小时,还研究了外周血细胞中γ干扰素(IFNγ)、白细胞介素8(IL8)、白细胞介素10(IL10)、单核细胞趋化蛋白1(MCP1)和肿瘤坏死因子α(TNFα)mRNA水平的变化。FcγRI表达在24小时后强烈增加,然后在整个治疗过程中保持在同一水平。相比之下,FcγRIII表达在第1天急剧下降,此后进一步降低。未观察到FcγRII有变化。中性粒细胞通过FcγRI发挥的ADCC在24小时后开始增加,在第5天达到峰值水平。细胞因子mRNA分析表明,24小时后IL8 mRNA出现可重复的强烈增加(13名儿童中有11名),而其他检测细胞因子的mRNA水平变化则更为多样(13名儿童中,IFNγ:3名;IL10:6名;MCP1:5名;TNFα:4名)。因此,本研究为在辅助免疫干预中联合使用G-CSF和单克隆抗体的优化治疗方案开辟了道路。